Ephrin type‑A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3‑kinase/Akt signalling pathway - Wikidata - awgldk - TriplyDB

Ephrin type‑A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3‑kinase/Akt signalling pathway

Ephrin type‑A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3‑kinase/Akt signalling pathway

http://www.wikidata.org/entity/Q34673530

about

Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.

P2860

Q47848908-1D2B5601-71A5-4B87-8CB5-2884AC9175B2

P2860

Ephrin type‑A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3‑kinase/Akt signalling pathway

http://www.wikidata.org/entity/Q34673530

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Ephrin type‑A receptor 2 regul ...... ‑kinase/Akt signalling pathway

@ast

Ephrin type‑A receptor 2 regul ...... ‑kinase/Akt signalling pathway

@en

Ephrin type‑A receptor 2 regul ...... ‑kinase/Akt signalling pathway

@nl

type

label

Ephrin type‑A receptor 2 regul ...... ‑kinase/Akt signalling pathway

@ast

Ephrin type‑A receptor 2 regul ...... ‑kinase/Akt signalling pathway

@en

Ephrin type‑A receptor 2 regul ...... ‑kinase/Akt signalling pathway

@nl

prefLabel

Ephrin type‑A receptor 2 regul ...... ‑kinase/Akt signalling pathway

@ast

Ephrin type‑A receptor 2 regul ...... ‑kinase/Akt signalling pathway

@en

Ephrin type‑A receptor 2 regul ...... ‑kinase/Akt signalling pathway

@nl

P1433

Q34673530-3F2BA9F3-992C-43E6-B074-961892B2CD17

P1476

Q34673530-5D279297-2F3A-4267-A9E8-77478F8A520D

P2093

Q34673530-0996C86C-41E6-444B-AB96-351AFCE5ECB2

Q34673530-232BA9B6-B55C-4A16-B5F6-08837752EFCF

Q34673530-3463BB16-25CD-4CD6-86E1-8A767E3A0253

Q34673530-36547D66-BC1C-468E-BA19-E74FDA6ED6F8

Q34673530-52B54141-03F9-4053-BDBE-404BEAB93DAC

Q34673530-5E1C7212-34B4-4F7C-9223-1CDC4FD9E06D

Q34673530-8CFB7D6D-9158-4F92-B80D-172D7DD5B2F4

Q34673530-93DD3BEA-6FAC-4BE1-91B0-1DCC3CE3F748

Q34673530-FA0CE39C-958C-4917-AF44-75AC9316F2BB

P2860

Q34673530-0CEE9F62-CF7C-4445-803A-9E970F34C3D4

Q34673530-175D0794-503E-4968-91D3-623EE2FC1CA0

Q34673530-21300976-4A50-4BED-B74B-A88305D75988

Q34673530-26A2C8EF-8923-49BB-AE0D-26F90A814B54

Q34673530-2BF0C2CD-EB2F-4664-834B-E85DB207A331

Q34673530-2BFC0B8E-F455-4A86-B087-5F261D6EA2A4

Q34673530-37A32352-61AF-4704-9250-F5F7EA2D3862

Q34673530-3911516E-7144-4C90-BA99-393B35E9B812

Q34673530-3AA962C2-6BD3-40C7-A258-F087B4BF08F1

Q34673530-3EB078A6-7D15-4556-8D4E-6CA1981FCA6F

P304

Q34673530-C6CA5D7D-180E-458D-8A3B-D424E4BF135C

P31

Q34673530-9A02AB29-A5E3-4E8D-8DD0-90C9562A3294

P356

Q34673530-A2B391F9-698E-40B9-BDD4-DB317F3A2AF6

P433

Q34673530-91510E50-8108-45D1-BA6A-09BCC826CFC8

P478

Q34673530-0781321D-8C64-4A2B-974C-603B8C410499

P577

Q34673530-493F9E01-C122-4DE2-AD5C-A7E70FB4978E

P5875

Q34673530-A93D0B3D-841B-4E60-98EF-3980DD32B75B

P698

Q34673530-FE021C59-A290-4684-BE7A-3318654A081E

P932

Q34673530-740F2CA3-342E-4712-9D19-0136E3755854

P356

P1433

Molecular Medicine Reports

P1476

Ephrin type‑A receptor 2 regul ...... ‑kinase/Akt signalling pathway

@en

P2093

Guo Li

http://www.w3.org/2001/XMLSchema#string

Pingqing Tan

http://www.w3.org/2001/XMLSchema#string

Shuling Ren

http://www.w3.org/2001/XMLSchema#string

Xin Zhang

http://www.w3.org/2001/XMLSchema#string

Yong Liu

http://www.w3.org/2001/XMLSchema#string

Yongquan Tian

http://www.w3.org/2001/XMLSchema#string

Yuanzheng Qiu

http://www.w3.org/2001/XMLSchema#string

Yunyun Wang

http://www.w3.org/2001/XMLSchema#string

Zhongwu Su

http://www.w3.org/2001/XMLSchema#string

P2860

Hypoxia-induced SM22α in A549 cells activates the IGF1R/PI3K/Akt pathway, conferring cellular resistance against chemo- and radiation therapy

mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.

ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers

Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway

Eph receptor signalling casts a wide net on cell behaviour

The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling

Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.

Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.

Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

P304

924-930

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MMR.2014.2799

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267745082

http://www.w3.org/2001/XMLSchema#string

P698

25351620

http://www.w3.org/2001/XMLSchema#string

P932

4262504

http://www.w3.org/2001/XMLSchema#string